Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
IR

NASDAQ · IRWD

Ironwood Pharmaceuticals, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$3.50

Down-$0.12 (-3.31%)

Updated Nov 1, 2026, 7:13 PM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
598.66M
P/E ratio
7.07
Dividend yield
0.00%
52-week range
$3.02 – $4.88
Volume
1.47M
Avg. volume
2.12M

Price performance · IRWD

IRWD price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

IRWD closed at $3.50 after 20 trading sessions, down 4.11% for the selected period.

Last close
$3.50
Period change
-4.11%
Period low
$3.46
Period high
$3.87
Daily close
View OHLC price history
IRWD OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$3.59$3.64$3.45$3.501.47M
Oct 29, 2026$3.65$3.695$3.575$3.621.37M
Oct 28, 2026$3.46$3.63$3.46$3.611.41M
Oct 27, 2026$3.52$3.545$3.45$3.511.66M
Oct 26, 2026$3.49$3.535$3.45$3.501.13M
Oct 23, 2026$3.52$3.536$3.38$3.461.26M
Oct 22, 2026$3.50$3.605$3.49$3.571.04M
Oct 21, 2026$3.68$3.69$3.521$3.551.52M
Oct 20, 2026$3.57$3.71$3.525$3.631.64M
Oct 19, 2026$3.53$3.59$3.475$3.561.68M
Oct 16, 2026$3.73$3.73$3.48$3.502.53M
Oct 15, 2026$3.63$3.87$3.63$3.772.04M
Oct 14, 2026$3.55$3.63$3.51$3.601.22M
Oct 13, 2026$3.74$3.78$3.545$3.592.11M
Oct 12, 2026$3.82$3.85$3.74$3.761.04M
Oct 9, 2026$3.88$3.95$3.81$3.821.72M
Oct 8, 2026$3.70$3.965$3.67$3.872.4M
Oct 7, 2026$3.58$3.87$3.54$3.752.05M
Oct 6, 2026$3.64$3.6791$3.595$3.631.87M
Oct 5, 2026$3.59$3.67$3.55$3.652.23M

Latest IRWD news

The latest Smart Investors Daily articles mentioning IRWD.

Stock researchCompany · Overview

IRWD research

Overview

Company profile and research snapshot.

Company profile

Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$3.80
Implied upside
—
Analysts
—
IRWD recent ratings
DateFirmRatingTarget
Feb 26, 2026CitizensMarket Outperform—
Jan 5, 2026Wells FargoEqual-Weight—
Jan 5, 2026CitizensMarket Outperform—
Nov 11, 2025Wells FargoEqual-Weight—
Apr 15, 2025Wells FargoEqual-Weight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 16, 2026

Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer

BOSTON, October 16, 2026--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that its Board of Directors appointed Chief Commercial Officer Tammi Gaskins as Chief Executive Officer and a member of the Board of Directors, effective January 1, 2027. On that date Chief Executive Officer Tom McCourt will retire from his current role and will remai

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By